Authors
Latest:
Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard TherapyAccording to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.
Latest:
Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast CancerChau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.
Latest:
Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCCChe-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.
Latest:
Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief ReviewThe emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.
Latest:
Rugo Covers Scope of Recent Breast Cancer AdvancesHope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.
Latest:
Building Foundations for Understanding Drug Mechanisms in OncologyA 2018 Giants of Cancer Care award winner for Drug Development, Joseph R. Bertino, MD, was an early pioneer in developing the understanding of methotrexate and its administration in cancer. His work has served as a platform for much broader investigation into the optimal use of other cancer agents. Along the way, Bertino has mentored many leaders in oncology and hematology and earned international recognition.
Latest:
Experts Share Hopes for the Future of Myeloma TreatmentThe data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.
Latest:
Dr Cremolini on the Implications of the TRANSMET Trial in Colorectal Liver MetastasesChiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.
Latest:
Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALLChing-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.
Latest:
Dr. Landen Discusses p53 Mutations in Ovarian CancerChip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the role of p53 mutations in patients with ovarian cancer.
Latest:
Dr Shah on Research to Minimize Surgical Intervention in Locoregional Breast CancerChirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.
Latest:
Dr. Atreya Discusses Maintenance Therapy for CRCChloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.
Latest:
Patient-Derived Xenografts Could Improve Precision Medicine OutcomesResearchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.
Latest:
Dr. Parker on the Optimal Timing of Salvage Therapy in Prostate CancerChris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.
Latest:
Useless Medical DevicesThroughout history, the public's pursuit of good health has, in the absence of scientific method or even common sense, motivated the creation of some downright ridiculous medical devices.
Latest:
Oncology Fellows: Reminding Ourselves of How Far We've ComeFor us, a group of 15 black students at Tulane University School of Medicine (TUSCOM), a visit to the Whitney Plantation in Edgard, Louisiana, was a no-brainer. The process of navigating medical school is pure hell at times, and you need inspiration wherever and whenever you can get it.
Latest:
Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic MelanomaChristian U. Blank, MD, PhD, discusses the OpACIN and OPACIN-neo trials examining ipilimumab plus nivolumab in stage III macroscopic melanoma.
Latest:
Christian Downs on the 34th National Oncology ConferenceChristian G. Downs, JD, MHA, executive director of the Association of Community Cancer Centers (ACCC), discusses the upcoming 34th National Oncology Conference, taking place October 18 to 20 in Nashville, Tennessee.
Latest:
Dr. Christian Gisselbrecht on Outcomes of Relapsed DLBCLChristian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
Latest:
Dr. Rolfo on Precision Medicine in Lung CancerChristian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.
Latest:
Dr. Rolfo Discusses the Potential Utility of CeritinibChristian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.
Latest:
Dr. Eskelund on Outcomes of TP53-Mutated MCLChristian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).
Latest:
Dr Hilton on Trastuzumab Deruxtecan in HER2+ Metastatic Breast CancerChristie J. Hilton, DO, discusses the first-line standard of care and changes in the second-line SOC, including key findings from the phase 3 DESTINY-Breast03 trial, in patients with HER2-positive metastatic breast cancer.
Latest:
Exciting New Options Emerge for HER2-Positive Breast CancerDuring a recent OncLive Peer Exchange®, experts in breast cancer research expressed optimism that new therapies would improve outcomes for patients with this challenging disease.
Latest:
Precision Medicine Goes Mainstream"Precision, personalized, individualized, targeted" - most oncologists are well acquainted with these terms. On Tuesday, President Obama introduced this concept to the nation in his State of the Union Address.
Latest:
Introducing the Oncology Specialty GroupOncology & Biotech News is now united with the experienced publishing, editorial, and creative staff of Oncology Net Guide and OncLive Nursing under the Oncology Specialty Group umbrella, which also includes our newest publication, Contemporary Oncology.
Latest:
Bounty of New HCC Therapies Spurs Need for More ResearchThe optimal integration of new drugs into the treatment paradigm of HCC requires several key developments, including greater research into biomarkers that would help inform therapy choices, earlier treatment for patients diagnosed with HCC, and clinical trials that test combination strategies.
Latest:
Telephone Counseling Boosts Spirits-and Immune Indicators-for Cervical Cancer SurvivorsPsychosocial telephone counseling intervention benefits mood and quality of life for cervical cancer survivors, including cancer-specific and gynecologic concerns.
Latest:
New Treatment Options Are in Play for Relapsed/ Refractory DLBCLUp to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.
